Mathur R, Bhaskaran Ok, Edwards E, Lee H, Chaturvedi N, Smeeth L, et al. Inhabitants traits within the 10-year incidence and prevalence of diabetic retinopathy within the UK: a cohort research within the Scientific Apply Analysis Datalink 2004–2014. BMJ Open. 2017;7:e014444.
Teo ZL, Tham Y-C, Yu M, Chee ML, Rim TH, Cheung N, et al. World prevalence of diabetic retinopathy and projection of burden by means of 2045: systematic overview and meta-analysis. Ophthalmology. 2021;128:1580–91.
Saitakis G, Roukas D, Hatziagelaki E, Efstathiou V, Theodossiadis P, Rizos E. Analysis of high quality of life and emotional disturbances in sufferers with diabetic retinopathy. Eur J Investig Well being Psychol Educ. 2023;13:2516–28.
Blankenship GW. Fifteen-year argon laser and xenon photocoagulation outcomes of Bascom Palmer Eye Institute’s sufferers taking part within the diabetic retinopathy research. Ophthalmology. 1991;98:125–8.
Wells J, Columbia SC A deeper take a look at protocols S and T. Assessment of ophthalmology. 2016. Out there from: https://www.reviewofophthalmology.com/article/a-deeper-look-at-protocols-s-and-t
Gross JG, Glassman AR, Liu D, Solar JK, Antoszyk AN, Baker CW, et al. 5-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized medical trial. JAMA Ophthalmol. 2018;136:1138–48.
Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized medical trial. JAMA. 2015;314:2137–46.
Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Scientific efficacy of intravitreal aflibercept versus panretinal photocoagulation for finest corrected visible acuity in sufferers with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, managed, part 2b, non-inferiority trial. Lancet. 2017;389:2193–203.
Simmonds MC, Llewellyn A, Walker RAE, Fulbright HA, Walton MJ, Hodgson R, et al. Anti-VEGF medication in contrast with laser photocoagulation for the remedy of proliferative diabetic retinopathy: a scientific overview and IPD meta-analysis. Well being Technol Assess. 2024.
Walton M, Bojke L, Simmonds M, Walker R, Llewellyn A, Fulbright H, et al. Anti–vascular endothelial development issue medication in contrast with panretinal photocoagulation for the remedy of proliferative diabetic retinopathy: a cost-effectiveness evaluation. Worth Well being. 2024;27:907–17.
Zhang W, Geng J, Sang A. Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF remedy in opposition to PRP alone for diabetic retinopathy: a scientific overview with meta-analysis. Entrance Endocrinol. 2022;13:807687.
Nationwide Institute for Well being and Care Excellence (NICE). Diabetic retinopathy. 2024. Out there from: https://www.good.org.uk/steerage/indevelopment/gid-ng10256
Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Solar JK. 5-year cost-effectiveness of intravitreous ranibizumab remedy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary evaluation of a randomized medical trial. JAMA Ophthalmol. 2019;137:1424–32.
Lin J, Chang JS, Smiddy WE. Price analysis of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy. Ophthalmology. 2016;123:1912–8.
Royle P, Mistry H, Auguste P, Shyangdan D, Freeman Ok, Lois N, et al. Pan-retinal photocoagulation and different types of laser remedy and drug therapies for non-proliferative diabetic retinopathy: systematic overview and financial analysis. Well being Technol Assess. 2015;19:1–248.
Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Ideas of excellent apply for choice analytic modeling in health-care analysis: Report of the ISPOR activity power on good analysis practices—modeling research. Worth well being. 2003;6:9–17.
Nationwide Institute for Well being and Scientific Excellence (NICE). Growing NICE tips: the guide. NICE course of and strategies PMG20. 2024. Out there from: https://www.good.org.uk/course of/pmg20
Maturi RK, Glassman AR, Josic Ok, Antoszyk AN, Blodi BA, Jampol LM, et al. Impact of intravitreous anti–vascular endothelial development issue vs sham remedy for prevention of vision-threatening problems of diabetic retinopathy: the protocol w randomized medical trial. JAMA Ophthalmol. 2021;139:701–12.
Haig J, Barbeau M, Ferreira A. Price-effectiveness of ranibizumab within the remedy of visible impairment on account of diabetic macular edema. J Med Econ. 2016;19:663–71.
Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy Ok, et al. Price-effectiveness of ranibizumab in remedy of diabetic macular oedema (DME) inflicting visible impairment: proof from the RESTORE trial. Br J Ophthalmol. 2012;96:688–93.
Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S. Price-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK sufferers with continual diabetic macular oedema thought of insufficiently aware of out there therapies. BMC Well being Serv Res. 2019;19:1–14.
Régnier SA, Malcolm W, Haig J, Xue W Price-effectiveness of ranibizumab versus aflibercept within the remedy of visible impairment on account of diabetic macular edema: a UK healthcare perspective. ClinicoEconomics and Outcomes Analysis. 2015:235-47.
Nationwide Institute for Well being and Care Excellence (NICE). Faricimab for treating diabetic macular oedema. Expertise appraisal steerage TA799. 2022. Out there from: https://www.good.org.uk/steerage/ta799
Nationwide Institute for Well being and Care Excellence (NICE). Brolucizumab for treating diabetic macular oedema. Expertise appraisal steerage TA820. 2022. Out there from: https://www.good.org.uk/steerage/ta820
Simmonds MC, Llewellyn A, Walker RAE, Fulbright HA, Walton MJ, Hodgson R, et al. Anti-VEGF medication in contrast with laser photocoagulation for the remedy of diabetic retinopathy: a scientific overview and meta-analysis. Well being Technol Assess. 2023. https://doi.org/10.3310/PCGV5709.
Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation modelling in ophthalmology: software to price effectiveness of ranibizumab and aflibercept for the remedy of moist age-related macular degeneration in the UK. Pharmacoeconomics. 2017;35:237–48.
Lang GE, Stahl A, Voegeler J, Quiering C, Lorenz Ok, Spital G, et al. Efficacy and security of ranibizumab with or with out panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy–the PRIDE research. Acta Ophthalmolog. 2020;98:e530–e9.
Wykoff CC, Ou WC, Khurana RN, Brown DM, Clark WL, Boyer DS. Lengthy-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension research. Br J Ophthalmol. 2018;102:631–6.
Workplace for Nationwide Statistics. Nationwide life tables–life expectancy within the UK: 2018 to 2020 2021. Out there from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2018to2020
Nationwide Institute for Well being and Care Excellence (NICE). Aflibercept for treating diabetic macular oedema. Expertise appraisal steerage TA346. 2015. Out there from: https://www.good.org.uk/steerage/ta346
Preis SR, Hwang S-J, Coady S, Pencina MJ, D’Agostino SrRB, Savage PJ, et al. Tendencies in all-cause and heart problems mortality amongst ladies and men with and with out diabetes mellitus within the Framingham Coronary heart Examine, 1950 to 2005. Circulation. 2009;119:1728–35.
Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324–30.
Nationwide Institute for Well being and Care Excellence (NICE). Age-related macular degeneration. NICE guideline NG82. 2018. Out there from: https://www.good.org.uk/steerage/ng82
Nationwide Institute for Well being and Care Excellence (NICE). Fluocinolone acetonide intravitreal implant for treating continual diabetic macular oedema after an insufficient response to prior remedy. Expertise appraisal steerage TA301. 2013. Out there from: https://www.good.org.uk/steerage/ta301
Nationwide Institute for Well being and Care Excellence (NICE). Dexamethasone intravitreal implant for treating diabetic macular oedema. Expertise appraisal steerage TA824. 2022. Out there from: https://www.good.org.uk/steerage/ta824
Bressler NM, Chang TS, Suñer IJ, High quality JT, Dolan CM, Ward J, et al. Imaginative and prescient-related operate after ranibizumab remedy by better-or worse-seeing eye: medical trial outcomes from MARINA and ANCHOR. Ophthalmology. 2010;117:747–56.e4.
Kay S, Ferreira A. Mapping the 25-item nationwide eye institute visible functioning questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthalmic Epidemiol. 2014;21:66–78.
Malkin AG, Goldstein JE, Perlmutter MS, Massof RW. Group LVRNS. Responsiveness of the EQ-5D to the results of low imaginative and prescient rehabilitation. Optom Vis Sci. 2013;90:799–805.
Claxton L, Malcolm WA, Hodgson R. PRM90—a comparability of modelling methods: affected person simulation verse markov modelling in ophthalmology. Worth Well being. 2014;17:A558–A9.
Karnon J, Haji Ali Afzali H. When to make use of discrete occasion simulation (DES) for the financial analysis of well being applied sciences? A overview and critique of the prices and advantages of DES. Pharmacoeconomics. 2014;32:547–58.
Davis S, Stevenson M, Tappenden P, Wailoo A. NICE DSU technical assist doc 15: cost-effectiveness modelling utilizing patient-level simulation. London: NICE; 2014.
Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good analysis practices—overview: a report of the ISPOR-SMDM Modeling Good Analysis Practices Activity Power–1. Med Decis Mak. 2012;32:667–77.
Davies R, Roderick P, Raftery J. The analysis of illness prevention and remedy utilizing simulation fashions. Eur J Operational Res. 2003;150:53–66.
Mohiuddin S, Busby J, Savović J, Richards A, Northstone Ok, Hollingworth W, et al. Affected person movement inside UK emergency departments: a scientific overview of using pc simulation modelling strategies. BMJ open. 2017;7:e015007.
Nationwide Institute for Well being and Scientific Excellence (NICE). Aflibercept resolution for injection for treating moist age‑associated macular degeneration. Expertise appraisal steerage TA294. 2013. Out there from: https://www.good.org.uk/steerage/ta294
Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Growth of a cost-effectiveness mannequin for optimisation of the screening interval in diabetic retinopathy screening. Well being Technol Assess. 2015;19:1–116.
